Illumina Accused by Rival of Monopolizing DNA-Sequencing Tools

Illumina Inc. was sued in federal court by a rival claiming the California biotech uses its monopoly power in the market for DNA-sequencing instruments to stomp out new competitors.

Illumina tried to push Element Biosciences Inc. out of the market by coercing customers to purchase its own products exclusively and selling its tools at below cost, Element alleged in a complaint filed Monday in the US District Court for the Northern District of California.

Illumina is a dominant provider of DNA-sequencing tools used by hospitals, universities, and research organizations. The company in 2023 agreed to divest cancer detection startup Grail ...